HAP Trading LLC Has $2.28 Million Holdings in Abbott Laboratories (ABT)
HAP Trading LLC boosted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 5.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 46,988 shares of the healthcare product maker’s stock after purchasing an additional 2,557 shares during the quarter. HAP Trading LLC’s holdings in Abbott Laboratories were worth $2,284,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the business. Heritage Trust Co raised its position in Abbott Laboratories by 10.1% during the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after buying an additional 200 shares during the period. Winfield Associates Inc. raised its position in Abbott Laboratories by 3.9% during the second quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after buying an additional 89 shares during the period. Thompson Davis & CO. Inc. raised its position in Abbott Laboratories by 17.7% during the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after buying an additional 370 shares during the period. JFS Wealth Advisors LLC raised its position in Abbott Laboratories by 349.0% during the second quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock valued at $131,000 after buying an additional 2,094 shares during the period. Finally, Motco raised its position in Abbott Laboratories by 213.7% during the second quarter. Motco now owns 2,880 shares of the healthcare product maker’s stock valued at $140,000 after buying an additional 1,962 shares during the period. Institutional investors own 71.01% of the company’s stock.
Several research firms recently weighed in on ABT. ValuEngine lowered Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 price target on the stock in a research report on Tuesday, October 31st. Barclays reissued an “overweight” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. Citigroup reaffirmed a “neutral” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Abbott Laboratories in a research report on Thursday, October 19th. Eight analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $56.81.
In other news, insider Sharon J. Bracken sold 2,188 shares of the company’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $56.12, for a total transaction of $122,790.56. Following the completion of the sale, the insider now owns 25,618 shares in the company, valued at approximately $1,437,682.16. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Alejandro D. Wellisch sold 2,153 shares of the company’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total value of $120,266.58. Following the sale, the insider now owns 10,256 shares of the company’s stock, valued at approximately $572,900.16. The disclosure for this sale can be found here. In the last quarter, insiders have sold 311,127 shares of company stock valued at $16,958,579. 0.76% of the stock is currently owned by corporate insiders.
Abbott Laboratories (NYSE ABT) opened at $54.79 on Wednesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. Abbott Laboratories has a 52-week low of $37.42 and a 52-week high of $56.69. The firm has a market capitalization of $95,228.27, a PE ratio of 22.70, a price-to-earnings-growth ratio of 2.05 and a beta of 1.06.
Abbott Laboratories (NYSE:ABT) last issued its earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.01. The company had revenue of $6.83 billion for the quarter, compared to analyst estimates of $6.72 billion. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The business’s revenue was up 28.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.59 EPS. sell-side analysts anticipate that Abbott Laboratories will post 2.49 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th were paid a dividend of $0.265 per share. The ex-dividend date was Thursday, October 12th. This represents a $1.06 annualized dividend and a dividend yield of 1.93%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 83.47%.
COPYRIGHT VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/hap-trading-llc-has-2-28-million-holdings-in-abbott-laboratories-abt/1746973.html.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.